An observational study in Acute Myocardial Infarction (AMI), sponsored by The Affiliated Hospital of Hangzhou Normal University. Not yet recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by The Affiliated Hospital of Hangzhou Normal University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 196 studies in Myocardial Infarction with a site in China — 64 open to participants now, 73 under way, 8 of them phase 3. Myocardial Infarction · China.
Among the 196 studies in Myocardial Infarction with a site in China, this one is the 57th largest by planned enrollment of the 89 observational ones that give a count, is one of 20 that started in 2026, is one of 89 observational ones, reaches primary completion later than 63 of the 72 other live ones, and was the 191st registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →64 of the 196 studies in Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Beijing Hospital · Sites in China
Ages 30–75
Peking University Third Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
Beijing Anzhen Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
196 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 22 · Phase 4 32
First in 1999; this study’s year is marked. 20 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is close to the median of 568 across 814 observational studies indexed under Myocardial Infarction.
Median enrollment 366 across the 107 interventional studies, 1,000 across the 89 observational. Of the 74 that completed or were terminated, 8 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 196 have an industry lead sponsor. The 10 most frequent:
The Affiliated Hospital of Hangzhou Normal University is the lead sponsor of 11 studies on the registry; 11 are open to participants now.
The Affiliated Hospital of Hangzhou Normal University has 1 study filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
21 of the studies in Myocardial Infarction with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07381803Phase 3Second Affiliated Hospital, Zhejiang University, School of MedicineThe Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction | 2026-12 |
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT07320625Phase 3Shanghai Zhongshan HospitalEfficacy of Montelukast on STEMl Patients | 2027-02-01 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT05891145Yangzhou UniversityRemimazolam for Postoperative Atrial Fibrillation | 2026-12 |
Add all 21 to your calendar (.ics) → With an account.
Among the 196 studies in Myocardial Infarction with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center, prospective, observational cohort study designed to investigate the association between aging-related characteristics and long-term outcomes in patients with acute myocardial infarction (AMI). Approximately 588 eligible participants will be consecutively enrolled and followed for at least 24 months. Clinical data, aging assessments, laboratory examinations, cardiac imaging, and blood samples will be collected to establish a clinical database and biobank. The study aims to identify aging-related prognostic biomarkers, develop a risk prediction model integrating clinical and aging-related indicators, and improve risk stratification and individualized management for patients with AMI.
The study population includes consecutively enrolled patients with acute myocardial infarction (AMI) and aging characteristics at a single center. Eligible participants will undergo standardized clinical assessment, aging evaluation, biospecimen collection, and prospective follow-up to investigate aging-related biomarkers and long-term clinical outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with acute myocardial infarction (AMI) and aging characteristics who meet the eligibility criteria will be consecutively enrolled in this prospective observational cohort. Participants will undergo comprehensive clinical evaluation, aging assessment, laboratory testing, cardiac imaging, biospecimen collection, and standardized follow-up for at least 24 months to investigate aging-related biomarkers, clinical outcomes, and prognostic risk prediction.
Major adverse cardiovascular events (MACE)
The occurrence of major adverse cardiovascular events, including all-cause death, cardiovascular death, recurrent myocardial infarction, hospitalization for heart failure, stent restenosis or thrombosis, severe bleeding, and aging-related serious adverse events.
Time frame: Baseline through 24 months of follow-up
All-cause mortality
Death from any cause during follow-up.
Time frame: Baseline through 24 months
Cardiovascular mortality
Death attributable to cardiovascular causes, including sudden cardiac death, heart failure, or cardiogenic shock.
Time frame: Baseline through 24 months
Hospitalization for heart failure
Hospital admission due to worsening heart failure requiring intravenous diuretics, inotropic agents, or vasoactive therapy.
Time frame: Baseline through 24 months
Recurrent myocardial infarction
New acute myocardial infarction occurring during follow-up according to standard diagnostic criteria.
Time frame: Baseline through 24 months
Aging-related serious adverse events
Aging-related adverse outcomes, including cognitive decline, frailty-related fracture after low-energy falls, or loss of activities of daily living.
Time frame: Baseline through 24 months
Prognostic performance of the aging-related risk prediction model
Predictive performance of the prognostic model integrating clinical characteristics, aging assessments, and aging-related biomarkers, evaluated using discrimination and calibration metrics.
Time frame: At completion of the 24-month follow-up
Start is estimated for Aug 2026; primary completion for Aug 2030, 48 months later.
Of 298 non-industry observational studies under Myocardial Infarction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 140. This study's planned 48 months is below that.
Counting every sponsor, half of 335 studies reached it within 48 months; a quarter within 18 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Affiliated Hospital of Hangzhou Normal University